¾±¶¯ÂöÇòÄÒËðÉËÄ£ÐÍ´óÊóºËת¼Òò×Ó¦ÊB±ä»¯Óë¾±¶¯ÂöѪ¹ÜÄÚĤÔöÉúµÄ¹ØÏµ¡î
½ª ê¿1£¬2£¬¶ÉÙºì2£¬ÁÎÓñ»ª1£¬Áõ»ª¶«1£¬2
¿ÎÌâ±³¾°£ºÄ¿Ç°ÒÑ֪ƽ»¬¼¡Ï¸°û¹ý¶ÈÔöÖ³ÊÇѪ¹ÜÖ§¼ÜÖÃÈë»òѪ¹Ü³ÉÐκó·¢ÉúÔÙÏÁÕµÄÖØÒª²¡Òò£¬µ«Æ½»¬¼¡Ï¸°ûÔöÖ³µÄÐźÅתµ¼Í¾¾¶Éв»ÍêÈ«Çå³þ¡£ÈÏʶƽ»¬¼¡Ï¸°ûÔöÖ³µÄÐźÅתµ¼Í¾¾¶¶ÔÓÚ²ûÃ÷Æä·¢²¡»úÖÆ¾ßÓÐÖØÒªÒâÒå¡£
Ó¦ÓÃÒªµã£º¢Ù±¾¿ÎÌâͨ¹ý½¨Á¢´óÊó¾±¶¯ÂöÄÚĤËðÉËÄ£ÐÍ£¬ÔÚÒÔÍùʵÑéµÄ»ù´¡ÉϽøÒ»²½¹Û²ìÁË´óÊó¾±¶¯ÂöÇòÄÒËðÉ˺óÐÂÉúÄÚĤÔöÖ³·¢ÉúÔÙÏÁÕ¼°¾Ö²¿ºËÒò×Ó¦ÊBµÄ±í´ï±ä»¯¡£¢Ú½á¹ûÌáʾËðÉËѪ¹Üµ¯ÐÔ»ØËõ¡¢ÐÂÉúÄÚĤÐγɼ°¸ºÐÔÖØËÜ£¨ÂýÐÔËõÕ£©ÊÇÔÙÏÁÕ·¢ÉúµÄÖ÷Òª»úÖÆ£¬ºËÒò×Ó¦ÊBÔÚÇòÄÒËðÉ˺ó¶ÔѪ¹Üƽ»¬¼¡µÄÔöÖ³ºÍÇ¨ÒÆ¼°ÔÙÏÁÕÆð×ÅÍÆ¶¯×÷Óá£
Ïà¹ØÁ´½Ó£ºÆ½»¬¼¡Ï¸°ûÇ¨ÒÆ¡¢ÔöÖ³ÊÇÐÂÉúÄÚĤÐγɼ°ÔÙÏÁյĹؼüÒòËØ£¬¶àÖִ̼¤ÒòËØ¾ùÄÜÓÕµ¼Æ½»¬¼¡Ï¸°ûÔöÖ³£¬½üÄêÑо¿±íÃ÷ºËת¼Òò×Ó¦ÊBµÄ¼¤»îÔÚÆ½»¬¼¡Ï¸°ûÔöÖ³ÖÐÆð×ÅÖÁ¹ØÖØÒªµÄ×÷Óá£ÿÿÿ
1»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ¸½ÊôкÍÒ½ÔºÐÄÄÚ¿Æ£¬ºþ±±Ê¡Î人ÊÐ 430022£»2ôßÄÏ´óѧµÚ¶þÁÙ´²Ò½Ñ§Ôº£¨ÉîÛÚÊÐÈËÃñÒ½Ôº£©ÐÄÄÚ¿Æ£¬¹ã¶«Ê¡ÉîÛÚÊÐ
518020
½ª 꿡Ů£¬1974ÄêÉú£¬¹ã¶«Ê¡ÉîÛÚÊÐÈË£¬ºº×壬»ªÖпƼ¼´óѧͬ¼ÃҽѧԺÔÚ¶Á²©Ê¿£¬Ö÷ÖÎҽʦ£¬Ö÷Òª´ÓʽéÈëÐÄÔಡѧµÄÑо¿¡£
Jiangxin99@tom.
com
ͨѶ×÷Õߣº¶Éٺ죬Ö÷ÈÎҽʦ£¬ôßÄÏ´óѧµÚ¶þÁÙ´²Ò½Ñ§Ôº£¨ÉîÛÚÊÐÈËÃñÒ½Ôº£©ÐÄÄÚ¿Æ£¬¹ã¶«Ê¡ÉîÛÚÊÐ 518020
dsh266@medmail.
com.cn
ÁÎÓñ»ª£¬Ö÷ÈÎҽʦ£¬»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ¸½ÊôкÍÒ½ÔºÐÄÄÚ¿Æ£¬ºþ±±Ê¡Î人ÊÐ 430022
liaoyh27@163.com
ÕªÒª
Ä¿µÄ:ÐÂÉúÄÚĤÒì³£ÔöÖ³ÊÇѪ¹Ü³ÉÐÎÊõºóÔÙÏÁÕµÄÖ÷ÒªÔÒò£¬µ«Æä»úÖÆÄ¿Ç°»¹²»Çå³þ¡£¹Û²ì´óÊó¾±¶¯ÂöÇòÄÒËðÉËÊõºóºËÒò×Ó¦ÊB±í´ïµÄ±ä»¯¼°ÆäÓ붯ÂöÄÚĤÔöÉúºÍѪ¹ÜÖØËܵĹØÏµ¡£
·½·¨£ºÊµÑéÓÚ2007-01/05ÔÚÉîÛÚÊÐÈËÃñÒ½Ôº¶¯ÎïʵÑéÖÐÐÄÍê³É¡£¢ÙʵÑé²ÄÁÏ£ºSPF¼¶ÐÛÐÔSD´óÊó36Ö»£¬ÌåÖÊÁ¿350 g ×óÓÒ¡£¢ÚʵÑé·½·¨£º½«´óÊóÒ»²à¾±¶¯ÂöÐÐÇòÄÒËðÉËÊõ×÷ΪʵÑé×飬ÁíÒ»²à¾±¶¯Âö×÷Ϊ¶ÔÕÕ×飬·Ö±ðÔÚ¾±×ܶ¯ÂöÇòÄÒËðÉ˺ó6 h£¬3£¬7£¬14£¬28 d ºóÂé×í²¢´¦ËÀ´óÊó£¬ÁôÈ¡Á½²à¾±×ܶ¯Âö±ê±¾¡£¢ÛʵÑéÆÀ¹À£ºÓ¦ÓÃ×éÖ¯ÐÎ̬ѧ·½·¨¼ì²âÄÚĤÔöÉú²¢½øÐмÆËã»úͼÏñ·ÖÎö£»Í¬Ê±Í¨¹ýÄý½ºµçÓ¾Ç¨ÒÆÂÊʵÑé²â¶¨ºËÒò×Ó¦ÊBµÄ»îÐÔ¡£
½á¹û£ºÄÉÈë´óÊó36Ö»£¬ÒòÔìģʧ°ÜºÍËÀÍöÅųý6Ö»£¬½øÈë½á¹û·ÖÎö30Ö»¡£¢ÙÇòÄÒËðÉ˺ó£¬ÄÚÄ¤Ãæ»ýÔÚ7£¬14£¬28 d Öð½¥Ôöºñ£¬ÄÚĤ/Öвã±ÈÂÊÔö³¤£¬Óë¶ÔÕÕ×é±È½Ï£¬²îÒìÏÔÖø£¨P < 0.05£©¡£Á½×éµÄÖÐÄ¤Ãæ»ýÎÞÃ÷ÏԱ仯¡£Ñª¹ÜÖØËÜÖ¸ÊýÔÚËðÉ˺ó6 h ×î´ó£¬Ö®ºó²»¶Ï¼õС¡£¢ÚºËÒò×Ó¦ÊBÔÚ¶ÔÕÕ×鼸ºõ²»±í´ï¡£¶øÇòÄÒËðÉ˺ó6 h ¼´¿É¼ûºËÒò×Ó¦ÊB±í´ï£¬²¢ÓÚ14 d ´ï¸ß·å£¬28 d ÈÔÓнÏÇ¿±í´ï¡£ÊµÑé×éºËÒò×Ó¦ÊB¸÷ʱ¼äµãÓë¶ÔÕÕ×é±È½Ï²îÒì¾ùÓÐÏÔÖøÐÔ(P < 0.05)¡£
½áÂÛ£º´óÊó¾±¶¯ÂöÇòÄÒËðÉËÊõºó£¬ºËÒò×Ó¦ÊB±»Ñ¸ËÙ¼¤»î²¢³ÖÐøÔö¼Ó£¬¿ÉÄÜÊÇÄÚĤÔöÉú¡¢Ñª¹ÜÖØËܵÄÖØÒª»úÖÆÖ®Ò»¡£
¹Ø¼ü´Ê£º¾±¶¯ÂöÇòÄÒ£»ºËת¼Òò×Ó£»Ñª¹ÜÄÚĤ£»ÔöÉú£»×éÖ¯¹¹½¨
½ªê¿£¬¶Éٺ죬ÁÎÓñ»ª£¬Áõ»ª¶«. ¾±¶¯ÂöÇòÄÒËðÉËÄ£ÐÍ´óÊóºËת¼Òò×Ó¦ÊB±ä»¯Óë¾±¶¯ÂöѪ¹ÜÄÚĤÔöÉúµÄ¹ØÏµ[J].Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´£¬2008£¬12(7):1230-1234 [www.zglckf.com/zglckf/ejournal/upfiles/08-7/7k-1230(ps).pdf]
ÖÐͼ·ÖÀàºÅ:R318
ÎÄÏ×±êʶÂë:A
ÎÄÕ±àºÅ:1673-8225
(2008)07-01230-05
ÊÕ¸åÈÕÆÚ£º2007-11-01 ÐÞ»ØÈÕÆÚ£º2008-01-22 (07-50-11-5977/WL¡¤A)
Correlation between nuclear factor-kappa B and vascular intimal hyperplasia in rat carotid artery after balloon catheter injury
Abstract
AIM:Neointimal hyperplasia is the main reason for vascular restenosis after angioplasty. The mechanism is uncertain. This study explored nuclear factor-¦ÊB (NF-¦ÊB) expression changes after balloon catheter injury and its correlation with intimal hyperplasia of carotid artery and vascular remodeling.
METHODS: The experiment was performed at Animal Experimental Center of Shenzhen People's Hospital from January to May 2007. ¢ÙThirty-six male SPF SD rats weighing about 350 g were selected, and subjected to balloon catheter injury at one side carotid artery as experimental group and the other side as control group. All rats were executed under anesthesia on the 6th hour, and 3rd, 7th, 14th, and 28th days after balloon injury, respectively to harvest common carotid artery samples. ¢ÚThe intimal thickness and the expression of NF-¦ÊB were detected by HE-staining and gel electrophoretic mobility shift assay (EMSA) methods.
RESULTS: Of the 36 rats, 6 were excluded due to failed modeling and death, and 30 rats were included in final analysis. ¢ÙThe thickening of intima was observed on the 3rd day after balloon injury, and became more significant on the 7th, 14th, and 28th days. The area ratio of intima/media was increased significantly compared with control group (P < 0.05). Vascular remodeling index reached the peak 6 hours after injury, and decreased thereafter. ¢ÚThe expression of NF-¦ÊB was hardly observed in the control group. In injured rat carotid artery, NF-¦ÊB expression was firstly found 6 hours after injury, peaked on the 14th day, and remained high expression to the 28th day. There were significant differences at each point between experiment and control groups (P < 0.05).
CONCLUSION: After balloon catheter injury in rats, NF-¦ÊB is rapidly activated and enhanced gradually, which may be one of the important mechanisms for intimal hyperplasia and vascular remodeling.
Jiang X, Dong SH, Liao YH, Liu HD. Correlation between nuclear factor-kappa B and vascular intimal hyperplasia in rat carotid artery after balloon catheter injury.Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2008;12(7):1230-1234(China) [www.zglckf.com/zglckf/ejournal/upfiles/08-7/7k-1230(ps).pdf]
0 ÒýÑÔ
¾µ¼¹Ü½éÈëÖÎÁÆÊÇĿǰÖÎÁƹÚÐIJ¡µÄÖØÒª·½·¨£¬ÓÈÆäÔÚ¼±ÐÔ¹ÚÂö×ÛºÏÕ÷»¼ÕßÖеÄÓ¦Óõõ½¿Ï¶¨¡£µ«Ñª¹Ü³ÉÐÎÊõºóÔÙÏÁÕÈ´ÑÏÖØÏÞÖÆÁËÆäÔ¶ÆÚÁÆÐ§£¬Õâ¾ÍʹµÃÔÙÏÁյķÀÖγÉΪµ±½ñÐÄѪ¹Ü²¡Ñо¿µÄÖØÒª¿ÎÌâÖ®Ò»¡£¶øÄ¿Ç°ÒÑÖªÔÙÏÁյķ¢²¡»úÖÆÖ÷ÒªÊÇÐÂÉúÄÚĤÐγɺÍѪ¹ÜÖØËÜ¡£ºËÒò×Ó¦ÊB (Nuclear factor-kappa£¬NF-¦ÊB)×÷ΪһÖÖÄܵ÷¿Ø¶àÖÖ»ùÒòµÄ¾ßÓжàÖÖЧӦµÄת¼Òò×Ó[1]£¬Òѱ»Ö¤Êµ²ÎÓ붯ÂöÖàÑùÓ²»¯¡¢Ñª¹Ü³ÉÐÎÊõºóÔÙÏÁÕºÍÆäËûѪ¹ÜÔöÖ³ÐÔ²¡±äµÈ²¡ÀíÉúÀí¹ý³Ì¡£¹Ê´Ë£¬±¾ÊµÑéÓ¦ÓôóÊó¾±¶¯ÂöÇòÄÒËðÉËÄ£ÐͽøÒ»²½¹Û²ìѪ¹ÜÄÚÆ¤ËðÉ˺óNF-¦ÊB»îÐԱ仯¼°ÆäÓëÄÚĤÔöÉúºÍѪ¹ÜÖØËܵĹØÏµ¡£
1 ²ÄÁϺͷ½·¨
Éè¼Æ£ºÖظ´²âÁ¿£¬¶Ô±È¹Û²ì¡£
µ¥Î»£º»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ¸½ÊôкÍÒ½Ôº£¬ÉîÛÚÊÐÈËÃñÒ½Ôº¡£
²ÄÁÏ£ºÊµÑéÓÚ2007-01/05ÔÚÉîÛÚÊÐÈËÃñÒ½Ôº¶¯ÎïʵÑéÖÐÐÄÍê³É¡£SPF¼¶ÐÛÐÔSD´óÊó36Ö»£¬ÌåÖÊÁ¿350 g ×óÓÒ£¬¹º×Թ㶫ʡʵÑ鶯ÎïÖÐÐÄ£¨¶¯ÎïºÏ¸ñÖ¤ºÅ£º0022488£©¡£
Ö÷ÒªÊÔ¼Á¼°ÒÇÆ÷£º100 g/L Ë®ºÏÂÈÈ©¡¢ÆÕͨ¸ÎËØÄÆ£¨±±¾©¶¦¹ú£©£»NE-PER Nuclear and Cytoplasmic Extraction Reagents£¨PIERCE£©£»LIGHTSHIFT EMSA KIT£¨PIERCE£©£»PMSF£¨PIERCE£©£»Àö´ººì¡¢¶þÛÏ»ùÒÒ´¼£¨Sigma£©¡£NF-¦ÊBµÄ̽ÕëÐòÁУ¨ÉúÎïËØ»¯±ê¼Ç£©£º5¡¯-AGT TGA GGG GAC TTT CCC AGG C -3¡¯£»3¡¯-TCA ACT CCC CTG AAA GGG TCC G -5¡¯¡£ÏÔ΢ÊÖÊõÆ÷е£¨ÉϺ£ÊÖÊõÆ÷е¶þ³§£©£»ÊÖÊõÏÔ΢¾µ¡¢ÆÕͨ¹âѧÏÔ΢¾µ£¨Olympus¹«Ë¾£¬ÈÕ±¾£©£»¾Æ¤¹Ú×´¶¯ÂöÇòÄÒµ¼¹Ü(2.0 mm¡Á10.0 mm£¬Medtronic¹«Ë¾)£»Ã¸±êÒÇ¡¢µçÓ¾²Û¡¢×ªÄ¤ÒÇ¡¢µçÓ¾ÒÇ¡¢×ªÄ¤²Û£¨Bio-RAD£¬ÃÀ¹ú£©£»´ÅÁ¦½Á°èÆ÷£¨ÉϺ£Ë¾ÀÖÒÇÆ÷³§£©£»ÍÑɫҡ´²£¨ÉϺ£ç÷ÌØ·ÖÎöÒÇÓÐÏÞ¹«Ë¾£©£»WS-¢óÐÍ¿¨Æ¬Ê½°µºÐ£¨Alphaimager¹«Ë¾£¬ÃÀ¹ú£©£»Äý½ºÍ¼Ïñ·ÖÎöϵͳBioSenSC300£¨ÉϺ£É½¸»¿ÆÑ§ÒÇÆ÷ÓÐÏÞ¹«Ë¾£©¡£
Éè¼Æ¡¢ÊµÊ©¡¢ÆÀ¹ÀÕߣºÊµÑéÉè¼ÆÎªµÚÒ»¡¢¶þ×÷Õߣ¬¸ÉԤʵʩΪµÚÒ»¡¢ËÄ×÷Õߣ¬ÆÀ¹ÀΪµÚÒ»¡¢¶þ¡¢Èý×÷Õß¡£µÚÒ»×÷ÕßΪÐÄÄڿƲ©Ê¿Éú£¬µÚ¶þ¡¢Èý×÷ÕßΪÐÄÄڿƲ©Ê¿Éúµ¼Ê¦£¬¾ù³¤ÆÚ´ÓÊÂÐÄѪ¹Ü²¡µÄÑо¿£¬²ÉÓÃä·¨ÆÀ¹À¡£
·½·¨£º
´óÊó¾±¶¯ÂöÇòÄÒµ¼¹ÜËðÉËÄ£Ð͵Ľ¨Á¢£º½«SD´óÊó¸¹Ç»×¢Éä100 g/L Ë®ºÏÂÈÈ©(0.3 mg/kg)Âé×í£¬´Óβ¾²Âö×¢Éä¸ÎËØÄÆ100 U/kg£¬È¡¾±²¿ÕýÖÐÇпڣ¬Ñ°ÕÒµ½×ó¾±×ܶ¯ÂöºÍ¾±Íâ¡¢¾±ÄÚ¶¯Âö·Ö²æ´¦£¬ÔÚ×ó¾±×ܶ¯Âö½üÐĶËÔÝʱ×è¶ÏѪÁ÷£¬´Ó¾±Í⶯Âö´¦Ðж¯ÂöÇпªÊõ£¬½«MedtronicÄÒµ¼¹Ü(2.0 mm¡Á10.0 mm)´ÓÇпڲåÈëÖÁ¾±×ܶ¯ÂöÔ¼1.5 cm£¬ÒÔ2 atm ³äÓ¯ÇòÄÒ£¬ÏòÔ¶ÐĶËÇ£Àµ¼¹Ü°þÍÑÄÚĤ£¬³éÈ¥ÉúÀíÑÎË®£¬ÔÙËÍÏò½üÐĶˣ¬Öظ´ÉÏÊö²Ù×÷3´Î£¬È»ºó³·³öµ¼¹Ü£¬½áÔú¾±Í⶯Âö£¬È¥³ýѪ¹Ü¼Ð£¬»Ö¸´ÑªÁ÷£¬·ìºÏÉ˿ڣ¬Ëͻض¯Îï¹Û²ìÊÒ¡£Êõºó¼¡×¢ÇàÃ¹ËØ20Íòµ¥Î»/d£¬¹²3 d£¬Ô¤·À¸ÐȾ¡£ÁíÈ¡¶Ô²à¾±×ܶ¯Âö×÷Ϊ¶ÔÕÕ£¬½ö·ÖÀëÓҲྱ×ܶ¯ÂöºÍ¾±ÄÚ¡¢Í⶯Âö£¬²»ÓèÇпª¡£
Ö¸±ê¼ì²â£º·Ö±ðÈ¡Á½²à¾±×ܶ¯Âö¼ìÑé¡£¶¯ÎïÂé×íºóÐо±²¿Æ¤·ôÇпª£¬·ÖÀë¾±×ܶ¯Âö£¬´Ó¾±×ܶ¯Âö·Ö²æ´¦¿ªÊ¼Ïò½üÐĶËÈ¡³öËðÉ˲¿Î»µÄ×ó¾±×ܶ¯ÂöÔ¼1.0 cm ×óÓÒ£¬ÆäÖÐ0.5 cm ¾±¶¯Âö½þÅÝÓÚÌå»ý·ÖÊýΪ0.1µÄ¼×È©Öй̶¨3~6 h£¨ÆäÓಿ·ÖѸËÙ·ÅÈëÒºµªÄÚ±£´æ£¬×¼±¸ÐÐNF-¦ÊB¼ì
²â£©£¬³£¹æÊ¯À¯°üÂñºóÐв¡ÀíÇÐÆ¬£¬Ã¿·Ý±ê±¾·ÇÁ¬ÐøÈ¡4´¦ÇÐÆ¬£¬ÇÐÆ¬ºñ¶È4 ¦Ìm£¬Ñ¡È¡ÇòÄÒËðÉ˺óѪ¹Ü½á¹¹±£ÁôÍêÕû¡¢Ñª¹ÜÐÎ̬½Ó½üÔÚÌåÉúÀí״̬µÄ¶¯Îï±ê±¾£¬·Ö±ðÓÚÊõºó 6 h£¬3£¬7£¬14£¬28 d ·ÖÅúÂé×íºó´¦ËÀ£¬±£Ö¤Ã¿¸öʱ¼äµã6Ö»´óÊ󣬳£¹æËÕľ¾«-ÒÁºìȾɫ£¬¹â¾µÏ¹۲ìѪ¹ÜÄÚĤÔöÉúÇé¿ö¡£ÀûÓÃQuantiment 520ÐͼÆËã»úͼÏñ·ÖÎöÒÇ·Ö±ð²âÁ¿¶¯Âö¹ÜÇ»Ãæ»ý(Lumen)¡¢ÄÚÄ¤Ãæ»ý(Intia)¡¢ÍâÄ¤Ãæ»ý(EEL)ºÍÖÐĤºá¶ÏÃæµÄÃæ»ý(Media)£¬²¢¼ÆËãÄÚĤ/ÖвãÃæ»ý±È¡£ÒÔÄÚµ¯Á¦Ä¤Çø±ðÄÚĤºÍÖÐĤ£¬²âÁ¿¹ÜÇ»Ãæ»ýÒÔ¼°ÄÚ¡¢ÍⵯÁ¦°å°üÈÆÃæ»ý(Ãæ»ýµ¥Î»¾ùÒÔmm2±íʾ)£»ÄÚÄ¤Ãæ»ý=ÄÚµ¯Á¦°å°üÈÆÃæ»ý£¹ÜÇ»Ãæ»ý£»ÖÐÄ¤Ãæ»ý=ÍⵯÁ¦°å°üÈÆÃæ»ý£ÄÚµ¯Á¦°å°üÈÆÃæ»ý£»Ñª¹ÜÖØËÜÖ¸Êý(VRI)=ËðÉ˲àÍⵯÁ¦°åÎ§ÈÆÃæ»ý (EELA)/¶ÔÕÕ²àÍⵯÁ¦°åÎ§ÈÆÃæ»ý(IELA)¡£
ÔöÉú³Ì¶È=ÄÚÄ¤Ãæ»ý(I)/ ÖÐÄ¤Ãæ»ý(M)¡£²âÁ¿²ÉÓõ¥Ã¤·¨£¬²âÁ¿ÕßΪÓ뱾ʵÑéÎÞ¹ØÕß¡£
Äý½ºµçÓ¾Ç¨ÒÆÂÊʵÑé¼ì²âNF-¦ÊB»îÐÔ£ººËµ°°×ÌáÈ¡£¬È¡Òºµª¶³´æ´óÊó¾±¶¯Âö×éÖ¯£¬¼ôË飬ҺµªÖÐÑгɷÛÄ©£¬400 ¦ÌL AÒºÖØÐü£¬±ùÉÏÅòÕÍ15 min£¬Õñµ´10 s¡£20 000 g ÀëÐÄ10 s£¬ÆúÉÏÇ壬25~40 ¦ÌL BÒºÖØÐüϸ°ûºË¡£±ùÉÏ·ÅÖÃ20 min£¬²»Ê±½Á¶¯£¬20 000 g ÀëÐÄ5 min£¬È¡ÉÏÇ壬²â¶¨µ°°×Ũ¶È£¬·Ö×°±£´æ-80 ¡æ¡£NF-¦ÊBµÄ̽ÕëÐòÁÐÓÃÉúÎïËØ»¯±ê¼Ç£¬È¡5 ¦ÌL ºËµ°°×ÌáÈ¡ÎïÓëÅäÖÆºÃµÄ»º³åÒºÅä³É×ÜÌå»ý20 ¦ÌL£¬ ½áºÏ·´Ó¦ÒºÔÚÊÒÎÂ20 min ½øÐнáºÏ·´Ó¦£¬È»ºóÐзDZäÐÔ¾Û±ûÏ©õ£°·Äý½ºµçÓ¾£¬100 V µçÓ¾80 min£¬100 V תĤ60 min£¬70 ¡æ ¹Ì¶¨1 h¡£»¯Ñ§·¢¹â¼ì²âÉúÎïËØ±ê¼ÇDNA£¬×îºó½«Ä¤·ÅÓÚ½º¾íºÐÖУ¬ÔÚXÉäÏßÏÂÏÔÓ°¡£²¢Í¬Ê±Éè¿Õ°×¶ÔÕÕ¡¢¾ºÕùÐÔ¶ÔÕÕ¼°·Ç¾ºÕùÐÔ¶ÔÕÕ¡£Ó¦ÓÃ50±¶Å¨¶Èδ±ê¼ÇµÄNF-¦ÊB¹ÑºËÜÕËá×÷¾ºÕù¶ÔÕÕÀ´Ö¤ÊµÆäÌØÒìÐÔ¡£·Ç¾ºÕùÐÔ¶ÔÕÕÑ¡ÓÃ50±¶Å¨¶Èδ±ê¼ÇµÄAP-1¹ÑºËÜÕËáÐòÁС£
Ö÷Òª¹Û²ìÖ¸±ê£º´óÊó¾±¶¯ÂöÇòÄÒËðÉ˺ó²»Í¬Ê±¼äµã×éÖ¯²¡Àí±ä»¯ºÍ¸÷Ö¸±ê±È½Ï¼°Ñª¹ÜÄÚNF-¦ÊB»îÐԱ仯¡£
ͳ¼ÆÑ§·½·¨£ºNF-¦ÊB»îÐÔ¼ì²â½á¹ûÓÃÄý½º³ÉÏñÓë·ÖÎöϵͳ½øÐлý·ÖÎü¹â¶È·ÖÎö¡£ÓɵÚÒ»×÷Õß²ÉÓÃSPSS 12.0Èí¼þÍê³Éͳ¼Æ´¦Àí¡£ÊµÑéÊý¾ÝÒÔ_x¡Às±íʾ£¬×é¼ä±È½Ï²ÉÓÃt¼ìÑ飬P < 0.05Ϊ²îÒìÓÐÏÔÖøÐÔÒâÒå¡£
2 ½á¹û
2.1 ʵÑ鶯ÎïÊýÁ¿·ÖÎö ÄÉÈë´óÊó36Ö»£¬ÒòÔìģʧ°ÜºÍËÀÍöÅųý6Ö»£¬½øÈë½á¹û·ÖÎö30Ö»¡£
2.2 ´óÊó¾±¶¯ÂöÇòÄÒËðÉ˺ó²»Í¬Ê±¼äµã¸÷Ö¸±ê±È½Ï ¼û±í1¡£
¹â¾µÏ¹۲ì¶ÔÕÕ×é¹ÜÇ»ÃæÄÚĤÎÞÃ÷ÏԱ仯£¬ÄÚÆ¤Ï¸°û¡¢ÄÚµ¯Á¦°åÍêÕû£¬½ö¼ûµ¥²ãѪ¹ÜÄÚÆ¤Ï¸°û£¬ÖÐĤÓÉ3~ 5²ã»·ÐÎÅÅÁеĵ¯ÐÔĤºÍƽ»¬¼¡Ï¸°û×é³É£¬ÅÅÁÐÕûÆë¡£ÄÚµ¯Á¦°å³Ê²¨ÀËÐΣ¬Óе¯ÐÔ£¬¼ûͼ1a¡£
ʵÑé×éËðÉ˺ó6 h ¿É¼ûѪ¹ÜÄÚĤ°þÍÑ£¬¾Ö²¿Å¼ÓÐÄÚµ¯Á¦°å¶ÏÁÑ£¬ÎÞÃ÷ÏÔÖÐĤ±ä»¯£¬ÍâĤÇá¶ÈÀ©ÕÅ£¬¼ûͼ1b¡£
ËðÉ˺ó3 d£¬ÄÚĤ¿ªÊ¼ÔöÉú£¬¿É¼ûÖв㵯Á¦°å½©Ö±£¬ÖÐĤÇá¶ÈÔöºñ£¬ÍâĤ¼ÌÐøÀ©ÕÅ£¬¼ûͼ1c¡£
ËðÉ˺ó7 d ÐÂÉúÄÚĤÐγɣ¬ÏÔÖøÔöºñ£¬ÔöÉúϸ°ûÅÅÁÐÎÉÂÒ£¬ÄÚÄ¤Ãæ»ý¡¢ÍâÄ¤Ãæ»ýÓë¶ÔÕÕ×é±È½Ï²îÒìÓÐÏÔÖøÐÔÒâÒå(P < 0.05)£¬µ«ÄÚÄ¤Ãæ»ýÀ©ÕŸüÃ÷ÏÔ£¬I/MÃæ»ý±ÈÓë¶ÔÕÕ×éÏà±È²îÒìÒ²ÓÐÏÔÖøÐÔ(P < 0.05)£¬¼ûͼ1d¡£
ËðÉ˺ó14 d£¬Ï¸°ûÍâ»ùÖÊÔö¼Ó£¬Æ½»¬¼¡Ï¸°ûÔöÉú£¬ÄÚĤ¼ÌÐøÔöºñ£¬ÍâÄ¤Ãæ»ý´ïµ½×î´ó£¬I/MÃæ»ý±È¼ÌÐøÔö´ó£¬¼ûͼ1e¡£
ÇòÄÒËðÉ˺ó28 d£¬¶¯Âö±ÚÃ÷ÏÔÔöºñ£¬ÒÔÄÚĤÔöºñΪÖ÷£¬¹ÜÇ»¼«¶ÈÏÁÕ£¬ÄÚĤÖÐÓдóÁ¿Ï¸°ûÍâ»ùÖÊÓëÆ½»¬¼¡Ï¸°û£¬¼ûͼ1f¡£
I/MÃæ»ý±È´Ëʱ×î´ó£¬Óë7£¬14 d ʱ±È½Ï²îÒìÓÐÏÔÖøÐÔÒâÒ壨P < 0.05£©£»7£¬14£¬28 d ¸÷×é¼ä±È½Ï²îÒìÏÔÖø£¨P < 0.05£©¡£Ñª¹ÜÖØËÜÖ¸ÊýÔÚÇòÄÒËðÉ˺ó6 h ´ïµ½×î´ó£¬ÆäºóΪ²»¶Ï¼õСµÄ¹ý³Ì¡£
2.3 ´óÊó¾±¶¯ÂöÇòÄÒËðÉ˺óѪ¹ÜÄÚNF-¦ÊB»îÐԵı仯
2.3.1 EMSAÌØÒìÐÔ¼ø¶¨ ÒõÐÔ¶ÔÕÕ(¼ûͼ2£¬Ó¾µÀ1)£ºÊÇÔÚ·´Ó¦ÎïÖмÓÉúÎïËØ±ê¼ÇNF-¦ÊB̽Õ룬¶øÎ´¼ÓºËµ°°×ÌáÈ¡Î¹Êδ¼ûµ½ÓÐNF-¦ÊB ½áºÏ̽ÕëµÄÖͺóÌõ´ø£»ÑôÐÔ¶ÔÕÕ(¼ûͼ2£¬Ó¾µÀ2)£ºÊÇÔÚ·´Ó¦ÎïÖмÓÉúÎïËØ±ê¼ÇNF-¦ÊB ̽ÕëºÍ¾±¶¯ÂöËðÉ˺ó3 d ºËµ°°×ÌáÈ¡Î³öÏַdz£Ç¿µÄNF-¦ÊB ÖͺóÌõ´ø¡£ÌØÒìÐÔ¾ºÕùÐÔÒÖÖÆ(¼ûͼ2£¬Ó¾µÀ3)£ºÊÇÔÚ·´Ó¦ÎïÖмÓÈë50±¶¹ýÁ¿µÄδ±ê¼ÇNF-¦ÊB ̽Õ룬¿ÉÏÔÖøµØ×è¶ÏÉúÎïËØ±ê¼ÇµÄNF-¦ÊB̽ÕëÓëºËµ°°×ÌáÈ¡ÎïÖÐNF-¦ÊBµÄ½áºÏ£¬Ã»Óмûµ½NF-¦ÊBÖͺóÌõ´øµÄ³öÏÖ¡£·ÇÌØÒìÐÔ¾ºÕùÐÔÒÖÖÆ(¼ûͼ2£¬Ó¾µÀ4)£º¼ÓÈë50±¶¹ýÁ¿µÄδ±ê¼ÇAP-1̽Õ룬¶ÔÉúÎïËØ±ê¼ÇNF-¦ÊB̽ÕëÓëºËµ°°×ÌáÈ¡ÎïÖÐNF-¦ÊB µÄ½áºÏÎÞÃ÷ÏÔÓ°Ïì¡£¶ÔÕÕÖÊ¿ØÊµÑéµÄ½á¹û±íÃ÷£¬¸Ã·½·¨ÓкܸߵÄÌØÒìÐÔ¡£

2.3.2 ²»Í¬×é¼äNF-¦ÊB»îÐÔ±È½Ï ¶ÔÕÕ×é´óÊóNF-¦ÊBµÄDNA½áºÏ»îÐԺܵͣ¬Óë¶ÔÕÕ×é±È½Ï£¬ÊµÑé×éNF-¦ÊB»îÐÔÃ÷ÏÔÔö¸ß(P < 0.05)¡£ÔÚÇòÄÒËðÉ˺ó6 h NF-¦ÊB±í´ï¼´Ã÷ÏÔÔö¼Ó£¬ËðÉ˺ó14 d NF-¦ÊB±í´ï´ï¸ß·å£¬ÊµÑé×é¸÷¸öʱ¼äµã¾ù½Ïǰһʱ¼ä¶ÎNF-¦ÊB±í´ïÔöÇ¿(P < 0.05)£»28 d ʱÈÔÓнϸ߱í´ï£¬µ«½Ï14 d ʱϽµ¡£Äý½ºµçÓ¾½á¹û¼ûͼ3£¬Í¼4¡£

3 ÌÖÂÛ
½üÄêÀ´Ñо¿½á¹û±íÃ÷£¬ÐÂÉúÄÚĤÐγɼ°Ñª¹ÜÖØËÜÊÇѪ¹Ü³ÉÐÎÊõºóÔÙÏÁÕµÄÖ÷ÒªÔÒò[2-4]¡£¶øÕâÒ»¹ý³ÌÊÇÓɶàÖÖϸ°ûÒò×ÓºÍÉú³¤Òò×ӽ鵼µÄ[5]£¬°üÀ¨¸´ÔÓµÄÑ×Ö¢·´Ó¦[6]¡¢Ñª¹Üƽ»¬¼¡Ï¸°ûÔöÖ³¡¢Ç¨ÒÆ¡¢µòÍö¼°Ï¸°û»ùÖÊ´óÁ¿·ÖÃںͶѻý[7]¡£
ĿǰÒÑÖªNF-¦ÊBÊǵ÷¿Ø¶àÖÖϸ°û»ùÒòת¼µÄ¹Ø¼üÒò×ÓÖ®Ò»[8]£¬ÓëһϵÁÐϸ°ûÒò×Ó¡¢Ñ×Ö¢½éÖʼ°µ°°×øÀàµÄ²úÉú¡¢Ï¸°ûÔöÖ³¡¢Ï¸°ûÍâ»ùÖʶѻýºÍϸ°ûµòÍöÓйØ[9-11]¡£ÔÚ¾²Ï¢Ï¸°ûÖÐNF-¦ÊBÒÔ·Ç»îÐÔÐÎʽ´æÔÚÓÚϸ°û½¬£¬µ±Íâ½çÒòËØ×÷ÓÃÓÚϸ°ûºó£¬NF-¦ÊBµÃÒÔ¼¤»î£¬½øÈëϸ°ûºË[12]£¬Óë°Ð»ùÒòµÄÆô¶¯×ÓºÍÔöÇ¿×ÓÖеĦÊBÐòÁÐÌØÒì½áºÏ£¬²ÎÓëÑ×Ö¢·´Ó¦¡¢ÄÚÆ¤Ï¸°û»î»¯¼°Æ½»¬¼¡Ï¸°ûÔöÖ³µÈÓйػùÒòµÄת¼ºÍµ÷¿Ø¡£½üÄêÑо¿±íÃ÷£¬NF-¦ÊBµÄ¼¤»îÊÇѪ¹Üƽ»¬¼¡Ï¸°ûÔöÖ³µÄ±Ø¾ºÍʼ¶¯»·½Ú[10]¡£CarterµÈ[13]±¨µÀNF-¦ÊB¿ÉÒÔ²ÎÓëÄýѪøÊÜÌ弤»î¼Á¡¢¼îÐÔ³ÉÏËάϸ°ûÉú³¤Òò×ӵȶàÖִ̼¤ÒòËØÓÕµ¼µÄѪ¹Üƽ»¬¼¡Ï¸°ûÔöÖ³£¬²¢ÇÒÔÚÆäÔöÖ³¹ý³ÌÖÐNF-¦ÊB¼¤»î¼°DNA½áºÏ»îÐÔÔö¼Ó¡£
ÓÉÓÚNF-¦ÊB¼¤»îºóºÍÏàÓ¦»ùÒòµ÷¿ØÇøÓòλµã½áºÏ²ÅÄÜ·¢»Óת¼µ÷¿ØµÄ×÷Ó᣹ʱ¾ÊµÑéͨ¹ýÄý½ºµçÓ¾Ç¨ÒÆÂÊʵÑé·½·¨¼ì²âNF-¦ÊBÓëDNAÉÏÌØÒìÐÔλµã½áºÏµÄÁ¿£¬´Ó¶ø±È½Ï²¢ÆÀ¼ÛÔÚѪ¹ÜÇòÄÒËðÉËÊõºóNF-¦ÊBµÄ»îÐԱ仯¼°Æä¹¦ÄÜ״̬¡£ÊµÑé·¢ÏÖNF-¦ÊBÔÚ¶ÔÕÕ×鼸ºõûÓбí´ï£¬¶øÊµÑé×éÔÚËðÉ˺󼴿̾ÍÃ÷ÏÔ±í´ï£¬²¢³Ê³ÖÐøÔö¼Ó£¬14 d ´ï¸ß·å£¬28 d ʱÈÔÓнϸ߱í´ï£¬ÕâÓëÎÄÏ×±¨µÀÏàËÆ[14]¡£±¾ÊµÑé×éÖ¯ÐÎ̬ѧ¼ì²é½á¹ûÏÔʾÇòÄÒËðÉ˿ɵ¼Ö¶¯ÂöÄÚÆ¤°þÍÑ£¬ÄÚĤµ¯Á¦°å¶ÏÁÑ£¬ËðÉ˺óÔöÉúµÄÄÚĤÖ÷ÒªÊÇÓÉÆ½»¬¼¡Ï¸°û¡¢´óÁ¿ÅÝÄϸ°û¡¢Ï¸°ûÍâ»ùÖʼ°ÉÙÁ¿µÄÏËά½áµÞ×éÖ¯¹¹³É£¬Æ½»¬¼¡Ï¸°û´óÁ¿ÔöÉúÓëϸ°û»ùÖÊÒ»ÆðÔì³ÉÁ˹ÜÇ»µÄÏÁÕ¡£
ÖÚËùÖÜÖª£¬Ñ×Ö¢·´Ó¦ÔÚѪ¹ÜËðÉ˺óÔÙÏÁÕ¹ý³ÌÖÐÆðµ½·Ç³£ÖØÒªµÄ×÷ÓÃ[15-16]£¬¶øËðÉËÒòËØÍ¨¹ý¼¤»îNF-¦ÊB¶ø´Ùʹ¸÷ÖÖϸ°ûÒò×Ó²úÉú£¬´Ó¶ø²ÎÓë²¢À©´óÑ×Ö¢·´Ó¦£¬ÒýÆðƽ»¬¼¡Ï¸°ûÔöÖ³Ç¨ÒÆ£¬Ñª¹ÜÖØËܵȣ¬¼ÓËÙÔÙÏÁյĽø³Ì¡£±¾ÊµÑé½á¹ûÏÔʾ£¬ÇòÄÒËðÉ˺óNF-¦ÊBµÄ¶¯Ì¬±ä»¯ÓëÄÚĤÔöÉú¡¢Ñª¹ÜÖØËܵĶ¯Ì¬±ä»¯Ç÷ÊÆÒ»Ö²¢ÉÔÌáǰ£¬ÌáʾÔÚ´óÊó¾±×ܶ¯ÂöÇòÄÒËðÉ˺ó£¬NF-¦ÊB±»¼¤»î£¬´Ó¶ø³ÉΪÒýÆðÄÚĤÔöÉúºÍÔÙÏÁÕµÄʼ¶¯»·½ÚÖ®Ò»¡£×ÛÉÏËùÊö£¬½«NF-¦ÊB×÷Ϊ·ÀÖÎÔÙÏÁÕµÄÒ»¸ö·Ö×Ó°ÐÏòÑо¿ÇÐÈëµã[17]£¬´Ó²»Í¬»·½ÚÒÖÖÆNF-¦ÊBµÄ»îÐÔ[18-20]£¬½«ÎªÔÙÏÁյķÀÖÎÌṩеÄÊֶΡ£
4 ²Î¿¼ÎÄÏ×
1 Chen F£¬Castranova V£¬Shi X£¬et al. New insights into the role of nuclear factor-kappaB£¬a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999;45(1):7-17
2 Fischman DL£¬Leon MB£¬Baim DS£¬et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary disease. Stent Restenosis Study Investigators. N Engl J Med 1994£»331(8)£º496-501
3 Lipke EA£¬West JL. Localized delivery of nitric oxide from hydrogels inhibits neointima formation in a rat carotid balloon injury model. Acta Biomater 2005£»1(6)£º597-606
4 Sheng ZY£¬Xie CY£¬Qiu L. Zhongguo Zuzhi Gongcheng Yanjiu Yu Linchuang Kangfu 2007£»11 (27)£º5311-5314
Ê¢ÕÑÔ°£¬Ð»´ºÒ㣬ÇñÀö.´óÊó¾±¶¯ÂöÇòÄÒËðÉ˺ó¹Ü±ÚѪ¹ÜÄÚÆ¤Éú³¤Òò×ÓºÍѪ¹ÜÄÚÆ¤Ï¸°û𤸽·Ö×Ó1 ±í´ï¼°À×¹«ÌÙ¶àß°µÄ¸ÉÔ¤.Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´[J].2007£¬11 (27)£º5311-5314
5 Yang X£¬Thomas DP£¬Zhang X£¬et al. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol 2006£»26(1)£º85-90
6 Kim HM£¬Bae SJ£¬Kim DW£¬et al. Inhibitory role of magnolol on proliferative capacity and matrix metalloproteinase-9 expression in TNF-alpha-induced vascular smooth muscle cells. Int Immunopharmacol 2007£»7(8)£º1083-1091
7 Davies MG£¬Hagen PO. Pathology of intimal hyperplasia. British J Surg 1994£»81£º1254-1269
8 Dobrovolskaia MA£¬Kozlov SV. Inflammation and cancer£ºwhen NF-kappaB amalgamates the perilous partnership. Curr Cancer Drug Targets 2005£»5(5)£º325-344
9 Hoffmann A£¬Levchenko A£¬Scott ML£¬et al. The IkappaB-NF-kappaB signaling module£ºtemporal control and selective gene activation. Science 2002£»298(5596)£º1241-1245
10 Wu CH£¬Chen CW£¬Chen HC£¬et al. Elucidating the inhibitory mechanisms of magnolol on rat smooth muscle cell proliferation. J Pharmacol Sci 2005£»99(4)£º392-399
11 Belllas RE£¬Lee JS£¬Sonenshein GE. Expression of a constitutive NF-¦ÊB -like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J Clin Invest 1995£»96(5)£º2521-2527
12 Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996£»14£º649-683
13 Carter BD£¬Kaltschmidt C£¬Kaltschmidt B£¬et al. Selective activation of NF-kappa B by nerve growth factor through the neurotrophin receptor p75. Science 1996£»272(5261)£º542-545
14 Hern¨¢ndez-Presa MA£¬Ortego M£¬Tun¨®n J£¬et al. Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 2003£»57(1)£º168-177
15 Wolf SC£¬Sauter G£¬Preyer M£¬et al. Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem 2007£»19(1-4)£º129-136
16 Lee S£¬Lim HJ£¬Park HY£¬et al. Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model. Atherosclerosis 2006£»186(1)£º29-37
17 Takeuchi K£¬Itoh H£¬Yonemitsu Y£¬et al. In vivo reduction of the nuclear factor-kappaB activity using synthetic cis-element decoy oligonucleotides suppresses intimal hyperplasia in the injured carotid arteries in rabbits. Surg Today 2007£»37(7)£º575-583
18 Peng Y£¬Gallagher SF£¬Haines K£¬et al. Nuclear factor-kappaB mediates Kupffer cell apoptosis through transcriptional activation of Fas/FasL. J Surg Res 2006£»130(1)£º58-65
19 Tse AK£¬Wan CK£¬Zhu GY£¬et al. Magnolol suppresses NF-kappaB activation and NF-kappaB regulated gene expression through inhibition of IkappaB kinase activation. Mol Immunol 2007£»44(10)£º2647-2658
20 Chandrasekar B£¬Mummidi S£¬Mahimainathan L£¬et al. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 2006£»281(22)£º15099-15109
|